Trial · NCT05610189
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Observed Plasma Concentration (Cmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Primary | Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Minimum Steady-state Plasma Concentration (Cmin,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Average Steady-state Plasma Concentration (Cavg,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Trough Concentration (Ctrough) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Time of Maximum Observed Concentration (Tmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Degree of Fluctuation [(Cmax - Cmin)/Cavg,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Peak-to-Trough Ratio (PTR) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Swing [(Cmax - Cmin)/Cmin,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Apparent Clearance of Tavapadon From Plasma (CL/F) | Pre-dose and at multiple timepoints post-dose up to Day 28 | |
| Secondary | Number of Participants With Adverse Events (AEs) and AEs by Severity | Up to Day 36 | |
| Secondary | Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values | Up to Day 29 | |
| Secondary | Number of Participants With Clinically Significant Changes in Vital Sign Values | Up to Day 29 | |
| Secondary | Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | Up to Day 29 | |
| Secondary | Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results | Up to Day 29 | |
| Secondary | Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) | Up to Day 29 | The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05610189/registered